The Global Resource For Connecting Buyers and Sellers

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs

BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO, Dec. 29, 2017 /PRNewswire/ — Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, thro…